Emerging therapies for multidrug resistant Acinetobacter baumannii

Trends in Microbiology

Volumn 21, Issue 3, 2013, Pages 157-163

  García Quintanilla, Meritxell ^a   Pulido, Marina R ^a   López Rojas, Rafael ^a   Pachón, Jerónimo ^a   McConnell, Michael J ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Acinetobacter baumannii; Antibiotic resistance; Antimicrobial peptides; Iron chelation therapy; Phage therapy; Vaccine

Indexed keywords

2,2' BIPYRIDINE; ANTIBIOTIC AGENT; APO 6619; BACTERIAL VACCINE; COLISTIN; DEFERIPRONE; DEFEROXAMINE; GALLIUM; GALLIUM NITRATE; GLYCYLCYCLINE DERIVATIVE; IRON CHELATING AGENT; NANOPARTICLE; NITRIC OXIDE; NITRIC OXIDE NANOPARTICLE; PHOTOSENSITIZING AGENT; POLYPEPTIDE ANTIBIOTIC AGENT; REACTIVE OXYGEN METABOLITE; TIGECYCLINE; UNCLASSIFIED DRUG; VK 28;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIAL LOAD; DRUG STRUCTURE; HUMAN; INFECTION PREVENTION; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR THERAPY; MULTIDRUG RESISTANCE; NITROSATIVE STRESS; NONHUMAN; NUCLEOTIDE SEQUENCE; PASSIVE IMMUNIZATION; PHAGE THERAPY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; REVIEW; SEPSIS; TREATMENT PLANNING; WOUND INFECTION;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; BIOLOGICAL THERAPY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS;

ACINETOBACTER BAUMANNII;

EID: 84875233801     PISSN: 0966842X     EISSN: 18784380     Source Type: Journal    
DOI: 10.1016/j.tim.2012.12.002     Document Type: Review

References (65)

1. McConnell M.J., et al. Acinetobacter baumannii: human infections, factors contributing to pathogenesis and animal models. FEMS Microbiol. Rev. 2013, 37:130-155.
2. Vila J., Pachón J. Therapeutic options for Acinetobacter baumannii infections. Expert Opin. Pharmacother. 2008, 9:587-599.
3. Wisplinghoff H., et al. Nosocomial bloodstream infections caused by Acinetobacter species in United States hospitals: clinical features, molecular epidemiology, and antimicrobial susceptibility. Clin. Infect. Dis. 2000, 31:690-697.
4. Chen Y.H., et al. Trends in the susceptibility of clinically important resistant bacteria to tigecycline: results from the Tigecycline In Vitro Surveillance in Taiwan study, 2006 to 2010. Antimicrob. Agents Chemother. 2012, 56:1452-1457.
5. López-Rojas R., et al. Acinetobacter baumannii resistant to colistin alters its antibiotic resistance profile: a case report from Spain. J. Infect. Dis. 2011, 204:1147-1148.
6. Rolain J.M., et al. Acinetobacter baumannii resistant to colistin with impaired virulence: a case report from France. J. Infect. Dis. 2011, 204:1146-1147.
7. Taccone F.S., et al. Successful treatment of septic shock due to pan-resistant Acinetobacter baumannii using combined antimicrobial therapy including tigecycline. Eur. J. Clin. Microbiol. Infect. Dis. 2006, 25:257-260.
8. Valencia R., et al. Nosocomial outbreak of infection with pan-drug-resistant Acinetobacter baumannii in a tertiary care university hospital. Infect. Control Hosp. Epidemiol. 2009, 30:257-263.
9. Haq I.U., et al. Bacteriophages and their implications on future biotechnology: a review. Virol. J. 2012, 9:9.
10. Lin N.T., et al. Isolation and characterization of phi AB2: a novel bacteriophage of Acinetobacter baumannii. Res. Microbiol. 2010, 161:308-314.
11. Yang H., et al. Isolation and characterization of a virulent bacteriophage AB1 of Acinetobacter baumannii. BMC Microbiol. 2012, 10:131.
12. Jin J., et al. Isolation and characterization of ZZ1, a novel lytic phage that infects Acinetobacter baumannii clinical isolates. BMC Microbiol. 2012, 12:156.
13. Lee C.N., et al. Lytic myophage Abp53 encodes several proteins similar to those encoded by host Acinetobacter baumannii and phage phiKO2. Appl. Environ. Microbiol. 2011, 77:6755-6762.
14. Popova A.V., et al. Isolation and characterization of wide host range lytic bacteriophage AP22 infecting Acinetobacter baumannii. FEMS Microbiol. Lett. 2012, 332:40-46.
15. Thawal N.D., et al. Effect of a novel podophage AB7-IBB2 on Acinetobacter baumannii biofilm. Curr. Microbiol. 2012, 65:66-72.
16. Yele A.B., et al. Novel lytic bacteriophage AB7-IBB1 of Acinetobacter baumannii: isolation, characterization and its effect on biofilm. Arch. Virol. 2012, 157:1441-1450.
17. Shen G.H., et al. Isolation and characterization of phikm18p, a novel lytic phage with therapeutic potential against extensively drug resistant Acinetobacter baumannii. PLoS ONE 2012, 7:e46537.
18. Li P., et al. Bioinformatic analysis of the Acinetobacter baumannii phage AB1 genome. Gene 2012, 507:125-134.
19. Soothill J.S. Treatment of experimental infections of mice with bacteriophages. J. Med. Microbiol. 1992, 37:258-261.
20. Espinal P., et al. Effect of biofilm formation on the survival of Acinetobacter baumannii on dry surfaces. J. Hosp. Infect. 2012, 80:56-60.
21. Carlton R.M. Phage therapy: past history and future prospects. Arch. Immunol. Ther. Exp. (Warsz) 1999, 47:267-274.
22. Merril C.R., et al. Long-circulating bacteriophage as antibacterial agents. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:3188-3192.
23. Smith H.W., et al. Factors influencing the survival and multiplication of bacteriophages in calves and in their environment. J. Gen. Microbiol. 1987, 133:1127-1135.
24. Thompson M.G., et al. Antibacterial activities of iron chelators against common nosocomial pathogens. Antimicrob. Agents Chemother. 2012, 56:5419-5421.
25. Neupane G.P., Kim D.M. Comparison of the effects of deferasirox, deferiprone, and deferoxamine on the growth and virulence of Vibrio vulnificus. Transfusion 2009, 49:1762-1769.
26. Moreau-Marquis S., et al. Tobramycin and FDA-approved iron chelators eliminate Pseudomonas aeruginosa biofilms on cystic fibrosis cells. Am. J. Respir. Cell Mol. Biol. 2009, 41:305-313.
27. Ibrahim A.S., et al. Combination therapy of murine mucormycosis or aspergillosis with iron chelation, polyenes, and echinocandins. Antimicrob. Agents Chemother. 2011, 55:1768-1770.
28. Ibrahim A.S., et al. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J. Clin. Invest. 2007, 117:2649-2657.
29. Fothergill J.L., et al. Novel therapeutic strategies to counter Pseudomonas aeruginosa infections. Expert Rev. Anti Infect. Ther. 2012, 10:219-235.
30. Fernandes S.S., et al. Identification of a new hexadentate iron chelator capable of restricting the intramacrophagic growth of Mycobacterium avium. Microbes Infect. 2010, 12:287-294.
31. Denny B.J., et al. Antimicrobial activity of a series of 1-alkyl-2-(4-pyridyl)pyridinium bromides against Gram-positive and Gram-negative bacteria. Med. Princ. Pract. 2005, 14:377-381.
32. de Leseleuc L., et al. In vitro and in vivo biological activities of iron chelators and gallium nitrate against Acinetobacter baumannii. Antimicrob. Agents Chemother. 2012, 56:5397-5400.
33. Fecteau M.E., et al. Antimicrobial activity of gallium nitrate against Mycobacterium avium subsp. paratuberculosis in neonatal calves. J. Vet. Intern. Med. 2012, 25:1152-1155.
34. Antunes L.C., et al. In vitro and in vivo antimicrobial activities of gallium nitrate against multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 2012, 56:5961-5970.
35. Fjell C.D., et al. Designing antimicrobial peptides: form follows function. Nat. Rev. Drug Discov. 2011, 11:37-51.
36. Vila-Farres X., et al. Update of peptides with antibacterial activity. Curr. Med. Chem. 2012, 19:6188-6198.
37. Giacometti A., et al. Comparative activities of cecropin A, melittin, and cecropin A-melittin peptide CA(1-7)M(2-9)NH2 against multidrug-resistant nosocomial isolates of Acinetobacter baumannii. Peptides 2003, 24:1315-1318.
38. Rodríguez-Hernández M.J., et al. Studies on the antimicrobial activity of cecropin A-melittin hybrid peptides in colistin-resistant clinical isolates of Acinetobacter baumannii. J. Antimicrob. Chemother. 2006, 58:95-100.
39. López-Rojas R., et al. Efficacy of cecropin A-melittin peptides on a sepsis model of infection by pan-resistant Acinetobacter baumannii. Eur. J. Clin. Microbiol. Infect. Dis. 2011, 30:1391-1398.
40. Conlon J.M., et al. Antimicrobial properties of brevinin-2-related peptide and its analogs: Efficacy against multidrug-resistant Acinetobacter baumannii. Chem. Biol. Drug Des. 2009, 74:488-493.
41. Conlon J.M., et al. Efficacy of six frog skin-derived antimicrobial peptides against colistin-resistant strains of the Acinetobacter baumannii group. Int. J. Antimicrob. Agents 2012, 39:317-320.
42. Conlon J.M., et al. Analogues of the frog skin peptide alyteserin-2a with enhanced antimicrobial activities against Gram-negative bacteria. J. Pept. Sci. 2012, 18:270-275.
43. Ostorhazi E., et al. Intramuscularly administered peptide A3-APO is effective against carbapenem-resistant Acinetobacter baumannii in mouse models of systemic infections. Biopolymers 2011, 96:126-129.
44. Ostorhazi E., et al. Preclinical advantages of intramuscularly administered peptide A3-APO over existing therapies in Acinetobacter baumannii wound infections. J. Antimicrob. Chemother. 2011, 65:2416-2422.
45. Lipsky B.A., et al. Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream. Clin. Infect. Dis. 2008, 47:1537-1545.
46. McConnell M.J., Pachón J. Active and passive immunization against Acinetobacter baumannii using an inactivated whole cell vaccine. Vaccine 2010, 29:1-5.
47. McConnell M.J., et al. Vaccination with outer membrane complexes elicits rapid protective immunity to multidrug-resistant Acinetobacter baumannii. Infect. Immun. 2011, 79:518-526.
48. McConnell M.J., et al. Outer membrane vesicles as an acellular vaccine against Acinetobacter baumannii. Vaccine 2011, 29:5705-5710.
49. Fattahian Y., et al. Protection against Acinetobacter baumannii infection via its functional deprivation of biofilm associated protein (Bap). Microb. Pathog. 2011, 51:402-406.
50. Luo G., et al. Active and passive immunization protects against lethal, extreme drug resistant-Acinetobacter baumannii infection. PLoS ONE 2012, 7:e29446.
51. Bentancor L.V., et al. Evaluation of the trimeric autotransporter Ata as a vaccine candidate against Acinetobacter baumannii infections. Infect. Immun. 2012, 80:3381-3388.
52. Bentancor L.V., et al. Poly-N-acetyl-beta-(1-6)-glucosamine is a target for protective immunity against Acinetobacter baumannii infections. Infect. Immun. 2012, 80:651-656.
53. Ashkenazi H., et al. Photodynamic effects of antioxidant substituted porphyrin photosensitizers on gram-positive and -negative bacterial. Photochem. Photobiol. 2003, 77:186-191.
54. Nitzan Y., et al. Eradication of Acinetobacter baumannii by photosensitized agents in vitro. J. Photochem. Photobiol. B 1998, 42:211-218.
55. Carpenter B.L., et al. Porphyrin-cellulose nanocrystals: a photobactericidal material that exhibits broad spectrum antimicrobial activity. Photochem. Photobiol. 2012, 88:527-536.
56. Tsai T., et al. Chitosan augments photodynamic inactivation of gram-positive and gram-negative bacteria. Antimicrob. Agents Chemother. 2011, 55:1883-1890.
57. Dai T., et al. Photodynamic therapy for Acinetobacter baumannii burn infections in mice. Antimicrob. Agents Chemother. 2009, 53:3929-3934.
58. Ragas X., et al. Photodynamic inactivation of Acinetobacter baumannii using phenothiazinium dyes: in vitro and in vivo studies. Lasers Surg. Med. 2010, 42:384-390.
59. Komerik N., et al. The effect of photodynamic action on two virulence factors of gram-negative bacteria. Photochem. Photobiol. 2000, 72:676-680.
60. Giuliani F., et al. In vitro resistance selection studies of RLP068/Cl, a new Zn(II) phthalocyanine suitable for antimicrobial photodynamic therapy. Antimicrob. Agents Chemother. 2010, 54:637-642.
61. Sulemankhil I., et al. Prevention and treatment of virulent bacterial biofilms with an enzymatic nitric oxide-releasing dressing. Antimicrob. Agents Chemother. 2012, 56:6095-6103.
62. Moller M.N., et al. Acceleration of nitric oxide autoxidation and nitrosation by membranes. IUBMB Life 2007, 59:243-248.
63. Fang F.C. Perspectives series: host/pathogen interactions. Mechanisms of nitric oxide-related antimicrobial activity. J. Clin. Invest. 1997, 99:2818-2825.
64. Fukuto J.M., et al. The chemical properties of nitric oxide and related nitrogen oxides. Nitric Oxide: Biology and Pathology 2000, 23-40. Academic Press. L.J. Ignarro (Ed.).
65. Mihu M.R., et al. The use of nitric oxide releasing nanoparticles as a treatment against Acinetobacter baumannii in wound infections. Virulence 2010, 1:62-67.